GW prices Sativex for MS pain

GW Pharmaceuticals wasted no time preparing to launch its newly-approved Sativex for MS patients. The UK developer says that it will sell the cannabis-based pain therapy for $14 a day. The Wall Street Journal notes that the approval in Britain should also be an encouragement to developers in the country, which have faced some hard times recently. GW spent 11 years developing Sativex and has high hopes for an eventual U.S. approval for cancer pain....

GW Pharma’s cannabis drug Sativex wins landmark approval

After a long and complex R&D odyssey, GW Pharmaceuticals (GWP) has finally won UK approval for Sativex, a drug derived from cannabis that can now be used to treat spasticity in MS patients. GW had hoped to get an approval in Britain back in 2003 but faced a long series of regulatory hurdles in its quest. Up until now GW has had to content itself with a 2005 approval in Canada. But Europe appears to be opening up. GW says that Spain appears ready to hand out an approval soon and other...